Desvenlafaxine Tablet, Extended Release
Product Images NDC 71205-586

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71205-586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-586-30 (Desvenlafaxine 100)

Desvenlafaxine 100mg is a medication produced by Alembic Pharmaceuticals Limited. Each package has 30 film-coated, extended release tablets that are round, biconvex and have a dark brown to red color. They are debossed with L350 on one side and plain on the other. The tablets are dispensed with a medication guide that should be given to each patient. The tablets should be kept at 20°-26°C (68"77°F) and out of reach of children.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

This appears to be a table displaying the effect of CYP3A4 inhibitors on the drug ketoconazole. It shows the geometric mean ratio of the maximum concentration (Cmax) and area under the curve (AUC) for ketoconazole with and without the inhibitors. The values in parentheses next to the ratios are the 30% confidence intervals. However, without additional context, it is difficult to interpret the significance of the changes in Cmax and AUC.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

The text represents a graph showing the estimated proportion of patients who experience relapse over time after randomization. The x-axis represents time in days, and the y-axis represents the percentage of patients experiencing relapse. The graph compares Desvenlafaxine Extended-Release Tablets 50mg to placebo. The data suggests that patients taking Desvenlafaxine have a lower estimated proportion of relapse compared to those taking a placebo.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

This appears to be a graph or chart showing the estimated proportion of patients experiencing relapse over time while taking Desvenlafaxine Extended-Release Tablets compared to placebo. The y-axis shows the percentage of patients experiencing relapse, while the x-axis shows the time to relapse in days from randomization. The chart seems to suggest that the Desvenlafaxine tablets may be more effective in preventing relapse than the placebo.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.